Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gardasil User Fee Date Extended By A Week

This article was originally published in The Pink Sheet Daily

Executive Summary

Merck's BLA submission date for its human papillomavirus vaccine Gardasil has been delayed by an "initial cursory review" by FDA, the company said

You may also be interested in...



Gardasil Granted Priority Review

Merck's human papillomavirus vaccine Gardasil has been granted priority review by FDA, the company announced Feb. 7

Gardasil Granted Priority Review

Merck's human papillomavirus vaccine Gardasil has been granted priority review by FDA, the company announced Feb. 7

Merck Takes A Shot At A June Approval For HPV Vaccine Gardasil

The firm requests a priority review for the human papillomavirus vaccine’s BLA, submitted Dec. 1.

Related Content

Topics

UsernamePublicRestriction

Register

PS063772

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel